Page last updated: 2024-08-21

pyrazines and Lymphoma, Non-Hodgkin

pyrazines has been researched along with Lymphoma, Non-Hodgkin in 58 studies

Research

Studies (58)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	32 (55.17)	29.6817
2010's	25 (43.10)	24.3611
2020's	1 (1.72)	2.80

Authors

Authors	Studies
Yaqub, F	1
Banerjee, SK; Das, BC; Das, S; Evans, T; Kambhampati, S; Karki, R; Schinke, C; Thapa, P; Van Veldhuizen, P; Verma, A; Weiss, LM	1
Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM	1
Chauncey, T; Deauna-Limayo, D; Dong, Z; Liu, D; Pilz, R; Wang, HY; Wang-Rodriguez, J; Yan, M; Zhao, F	1
Evens, AM; Gordon, LI; Helenowski, I; Lossos, IS; Millenson, M; Rosen, ST; Smith, MR; Winter, JN	1
Kato, H; Kinoshita, T	1
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A	1
Batalo, MS; Bose, P; Grant, S; Holkova, B	1
Abella-Dominicis, E; Barr, PM; Cheson, BD; Di Paolo, J; Dreiling, LK; Friedberg, JW; Greenwald, DR; Hawkins, MJ; He, J; Hu, J; Joshi, A; Lee, H; Liem, AK; Mclntyre, RE; O'Brien, SM; Reddy, A; Saylors, GB; Spurgeon, SE	1
Czuczman, MS; O'Connor, OA	1
Cheson, BD	2
Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L	1
Delmonte, A; Ghielmini, M; Sessa, C	1
Balasubramanian, S; Bhalla, S; Buggy, J; David, K; Evens, AM; Gordon, LI; Mauro, L; Miller, R; Prachand, S; Sirisawad, M	1
Hamlin, P; MacGregor-Cortelli, B; Moskowitz, CH; Muzzy, J; O'Connor, O; Schenkein, DP; Straus, D; Trehu, E; Wright, J; Zelenetz, AD	1
Bargetzi, M; Heizmann, M; Kotrubczik, N; Moosmann, P; Wernli, M	1
Cohen, LJ; Humphreys, BD; Laubach, JP; Rennke, HG	1
Rummel, M	1
Cheng, B; Cheung, YK; Lee, SM	1
Jiang, C; Yang, XG	1
Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z	1
Dreyling, M	1
Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W	1
Dalal, N; Kozolff, M; Nabhan, C; Starr, A; Tolzien, K; Villines, D	1
Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A	1
Gotoh, K; Ito, Y; Iwata, S; Kamakura, M; Kawada, J; Kimura, H; Nishiyama, Y; Saito, T	1
Feng, H; Girgis, S; Hellmann, A; Louw, VJ; Patel, H; Rule, S; Shpilberg, O; Skee, DM; van de Velde, H; Walewski, J	1
Arcila, M; Gerecitano, J; Gonzalez, C; Gounder, S; Lin, D; McDonald, A; Mulligan, G; O'Connor, OA; Ogilvie, S; Teruya-Feldstein, J; Zhang, Z; Zheng, J	1
Feldman, T; Goy, A; Mato, AR	1
Cilley, J; Evens, AM; Gallot, L; Gordon, LI; Larson, A; Patton, D; Rademaker, A; Roy, R; Spies, S; Variakojis, D; Winter, JN	1
Ghielmini, M; Stathis, A	1
Argnani, L; Baccarani, M; Ballerini, F; Broccoli, A; Casadei, B; Derenzini, E; Fabbri, A; Gandolfi, L; Guarini, A; Merla, E; Pavone, V; Pellegrini, C; Puccini, B; Quintini, G; Quirini, F; Stefoni, V; Vigliotti, ML; Zinzani, PL	1
Jäger, U	1
Reddy, GK	1
Gilles, F; Goy, A	1
O'Connor, OA	1
Adams, J; Choi, E; Dumetrescu, O; Esseltine, D; Hamlin, P; MacGregor-Cortelli, B; Moskowitz, C; Muzzy, J; O'Connor, OA; Portlock, C; Schenkein, D; Straus, D; Stubblefield, M; Trehu, E; Wright, J; Zelenetz, AD	1
Chaudhary, PM; Matta, H	1
Dalton, WS; Holle, L; Jung, L	1
Davidson, T; Schwartz, R	1
Anderson, KC; Hideshima, T; Mitsiades, CS; Mitsiades, N; Richardson, PG	1
Zelenetz, A	1
Orlowski, RZ	1
Jaehde, U; Scheulen, ME; Simons, S	1
Coleman, M; Furman, RR; Leonard, JP	1
O'Connor, OA; Paoluzzi, L	1
Bohlius, J; Engert, A; Hülsewede, H; Kober, T	1
Esseltine, D; MacGregor-Cortelli, B; Muzzy, J; O'Connor, OA; Schenkein, D; Scher, H; Slovin, S; Stubblefield, MD; Wright, J	1
Nguyen, CA; Romaguera, J; Wang, M; Zhang, L; Zhou, Y	1
Boral, A; Busam, K; Esseltine, D; Gerecitano, J; Gonen, M; Goy, A; MacGregor-Cortelli, B; Neylon, E; O'Connor, OA; Sachs, D; Schenkein, D; Teruya-Feldstein, J; Wright, J	1
Ballestrero, A; Brossart, P; Grünebach, F; Nencioni, A; Patrone, F	1
Jin, J; Li, Y; Meng, H; Qian, J; Tong, Y	1
Antonio, S; Daniele, V; Enrico, O; Gabriele, B; Giulia, C; Mario, P; Nadia, C; Sara, G	1
Hatake, K; Terui, Y; Yokoyama, M	1
Jin, F; Joshi, I; Smith, MR	1
Friedberg, JW; Hagemeister, FB; Leonard, JP; Levine, AM	1

Reviews

23 review(s) available for pyrazines and Lymphoma, Non-Hodgkin

Article	Year
Boron chemicals in diagnosis and therapeutics. Future medicinal chemistry, 2013, Volume: 5, Issue:6 Topics: Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Fluorescent Dyes; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species	2013
[Molecular target therapy for non-Hodgkin lymphoma]. Nihon rinsho. Japanese journal of clinical medicine, 2014, Volume: 72, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Pyrazines; Rituximab; Signal Transduction	2014
Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:16 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Inhibitors; Pyrazines	2014
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation. Leukemia & lymphoma, 2008, Volume: 49 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines; Thalidomide	2008
Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas. The oncologist, 2009, Volume: 14, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Clinical Trials as Topic; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lymphoma, Non-Hodgkin; Oligonucleotides, Antisense; Proteasome Inhibitors; Protein Kinase C; Pyrazines; Sirolimus	2009
The spectrum of kidney involvement in lymphoma: a case report and review of the literature. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010, Volume: 56, Issue:6 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Kidney; Lymphoma, Non-Hodgkin; Male; Prognosis; Pyrazines; Renal Insufficiency; Rituximab; Treatment Outcome	2010
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. Journal of the National Comprehensive Cancer Network : JNCCN, 2010, Volume: 8 Suppl 6 Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide	2010
[Malignant lymphoma: individualized treatment according to biological and clinical risk factors]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:14 Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ki-1 Antigen; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precision Medicine; Prognosis; Pyrazines; Risk Factors; Rituximab; Survival Rate; Waldenstrom Macroglobulinemia	2011
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. The oncologist, 2012, Volume: 17, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Translational Research, Biomedical	2012
Hematologic malignancies: new developments and future treatments. Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13 Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides	2002
Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clinical lymphoma, 2004, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Death; Clinical Trials as Topic; Cysteine Endopeptidases; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Models, Biological; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines	2004
The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. Current treatment options in oncology, 2004, Volume: 5, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Risk Assessment; Survival Rate	2004
Discovery, Development, and clinical applications of bortezomib. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors	2004
Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors	2004
Proteasome inhibitors as therapeutics. Essays in biochemistry, 2005, Volume: 41 Topics: Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines	2005
[Bortezomib]. Deutsche medizinische Wochenschrift (1946), 2006, Feb-03, Volume: 131, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Humans; Kidney Neoplasms; Leukemia; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Pyrazines	2006
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. International journal of cancer, 2006, Sep-01, Volume: 119, Issue:5 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome	2006
Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2006, Volume: 20, Issue:1 Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines	2006
Fourth biannual report of the Cochrane Haematological Malignancies Group. Journal of the National Cancer Institute, 2006, Apr-19, Volume: 98, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine	2006
Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert review of anticancer therapy, 2006, Volume: 6, Issue:7 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Pyrazines; Waldenstrom Macroglobulinemia	2006
Proteasome inhibitors: antitumor effects and beyond. Leukemia, 2007, Volume: 21, Issue:1 Topics: Boronic Acids; Bortezomib; Cardiovascular Diseases; Dendritic Cells; Graft vs Host Disease; Humans; Lymphocytes; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction	2007
[Recent progress in rituximab therapy and its resistance--how do we overcome?]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CD55 Antigens; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Point Mutation; Prednisone; Pyrazines; Rituximab; Vincristine	2007
Combination treatment approaches and novel therapies for lymphoma. Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:8 Suppl 12 Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cancer Vaccines; Cytokines; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Stem Cell Transplantation	2007

Trials

15 trial(s) available for pyrazines and Lymphoma, Non-Hodgkin

Article	Year
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous	2014
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. British journal of haematology, 2014, Volume: 166, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome	2014
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood, 2016, 05-19, Volume: 127, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Cytokines; Early Termination of Clinical Trials; Female; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Pneumonia; Protein Kinase Inhibitors; Purines; Pyrazines; Quinazolinones; Salvage Therapy; Syk Kinase	2016
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clinical pharmacokinetics, 2009, Volume: 48, Issue:3 Topics: Aged; Anti-Ulcer Agents; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Omeprazole; Proton Pump Inhibitors; Pyrazines	2009
Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. Leukemia & lymphoma, 2010, Volume: 51, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome	2010
Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin's lymphoma. Chinese medical journal, 2010, Volume: 123, Issue:22 Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pyrazines; Treatment Outcome; Young Adult	2010
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8 Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome	2011
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. American journal of hematology, 2011, Volume: 86, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous	2011
Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Grading; Pyrazines; Rituximab; Treatment Outcome	2012
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. Clinical pharmacokinetics, 2011, Dec-01, Volume: 50, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Dexamethasone; Drug Combinations; Enzyme Induction; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Rifampin	2011
Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma. British journal of haematology, 2012, Volume: 158, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Proteins; Protein Array Analysis; Pyrazines; Recurrence; Treatment Outcome	2012
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. Leukemia & lymphoma, 2013, Volume: 54, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Pyrazines; Radioimmunotherapy; Recurrence; Treatment Outcome; Yttrium Radioisotopes	2013
New developments with bortezomib in treating multiple myeloma. Clinical lymphoma, 2004, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Renal Insufficiency; Treatment Outcome	2004
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Protease Inhibitors; Pyrazines	2005
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? British journal of haematology, 2006, Volume: 134, Issue:4 Topics: Aged; Boronic Acids; Bortezomib; Drug Hypersensitivity; Female; Humans; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Protease Inhibitors; Pyrazines; Skin; Skin Diseases, Vascular; Treatment Outcome	2006

Other Studies

20 other study(ies) available for pyrazines and Lymphoma, Non-Hodgkin

Article	Year
2019 ASH Annual Meeting. The Lancet. Haematology, 2020, Volume: 7, Issue:1 Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pyrazines	2020
CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. European journal of haematology, 2014, Volume: 93, Issue:1 Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pyrazines; Rituximab	2014
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma. Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine	2014
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine	2008
PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, May-15, Volume: 15, Issue:10 Topics: Aged; Antineoplastic Agents; Apoptosis; Benzofurans; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma; Lymphoma, Non-Hodgkin; Male; Membrane Potential, Mitochondrial; Middle Aged; NF-kappa B; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured	2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II. Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 4 Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Inhibitors; Pyrazines	2004
Continual reassessment method with multiple toxicity constraints. Biostatistics (Oxford, England), 2011, Volume: 12, Issue:2 Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Clinical Trials, Phase I as Topic; Computer Simulation; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epidemiologic Research Design; Humans; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Models, Statistical; Neoplasms; Neurotoxicity Syndromes; Prednisolone; Probability; Pyrazines; Statistical Distributions; Thrombocytopenia; Vincristine	2011
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Experimental hematology, 2011, Volume: 39, Issue:10 Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein	2011
Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells. Cancer science, 2012, Volume: 103, Issue:2 Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line; Cell Survival; Child; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Pyrazines; T-Lymphocytes; Valproic Acid	2012
New agents for the treatment of lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Immunotoxins; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Proteasome Inhibitors; Pyrazines	2012
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. Hematological oncology, 2013, Volume: 31, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Off-Label Use; Peripheral Nervous System Diseases; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Signal Transduction; Transplantation, Autologous; Treatment Outcome	2013
Innovative strategies in lymphoma therapy. Wiener klinische Wochenschrift, 2003, Aug-14, Volume: 115, Issue:13-14 Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Forecasting; Genetic Therapy; Humans; Immunoconjugates; Immunotherapy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Protease Inhibitors; Proteomics; Pyrazines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Signal Transduction; Survival Analysis; Thalidomide; Time Factors; Vincristine	2003
Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases. ONS news, 2004, Volume: 19, Issue:9 Suppl Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nursing Assessment; Oncology Nursing; Protease Inhibitors; Proteasome Inhibitors; Pyrazines	2004
The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer biology & therapy, 2005, Volume: 4, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Herpesviridae Infections; Herpesvirus 8, Human; Humans; Lymphoma, Non-Hodgkin; Pyrazines; Tumor Cells, Cultured	2005
Proteasome inhibitors in non-Hodgkin's lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN, 2005, Volume: 3 Suppl 1 Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines	2005
The ubiquitin proteasome pathway from bench to bedside. Hematology. American Society of Hematology. Education Program, 2005 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin	2005
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:5 Topics: Aged; Boronic Acids; Bortezomib; Electrodiagnosis; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Nervous System Diseases; Prostatic Neoplasms; Protease Inhibitors; Pyrazines	2006
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. American journal of hematology, 2007, Volume: 82, Issue:5 Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chickenpox; Dexamethasone; Disease Susceptibility; Doxorubicin; Female; Herpesvirus 3, Human; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Virus Activation	2007
Unexpected cardiotoxicity in haematological bortezomib treated patients. British journal of haematology, 2007, Volume: 138, Issue:3 Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Heart Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines	2007
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-15, Volume: 13, Issue:18 Pt 2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 9; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Phosphorylation; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha	2007